Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD). An application filing notification letter from the FDA is expected before the end of Q3 2021.

Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Submits New Drug Application to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2021 Results - Earnings Call Transcript

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -60.87% and -30.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue Estimates

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share decreased 131.25% over the past year to ($0.74), which missed the estimate of ($0.45).

Marinus Pharmaceuticals: Q1 Earnings Insights

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #earnings--Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #earnings--Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call for Monday, May 17 at 8:30 AM Eastern

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. plans to release financial results for the first quarter ended March 31, 2021 after the market close on May 13, 2021.

Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals announced Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan as Vice President of Sales.

Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BOD--Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors

Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors

Marinus Pharmaceuticals, Inc.'s (MRNS) CEO Dr. Scott Braunstein on Q4 2020 Results - Earnings Call Transcript

RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus provided an update on its clinical and regulatory development activities and reported its financial results for 4Q

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc., today unveiled its new brand identity.

Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals will participate in multiple investor healthcare and life sciences conferences.

Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #earnings--Marinus Pharmaceuticals will release the financial results for the fourth quarter and fiscal year ended December 31, 2020 on March 9 via webcast.

Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD.

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)

RADNOR, Pa.--(BUSINESS WIRE)-- #HCWBioConnect--Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference.

Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C.

CymaBay Therapeutics

Editas Medicine

Intellia Therapeutics

Vertex Pharmaceuticals

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

5 Disruptive Biotech Stocks With Solid Long-Term Potential

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI).

Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index

Arcturus Therapeutics

iBio

This can happen when a company holds out its hand for a big chunk of fresh capital.

News for Marinus Pharmaceuticals Stock (MRNS)